Replies to post #104590 on Biotech Values

[alertmeipp]

eventually, we will all be.... u know.

[DewDiligence]

…isn't the AF trial just another step for the broader indication?

Not really—stroke prevention secondary to AF is an indication with its own unique characteristics. Success by the new oral anticoagulants in AF/stroke prevention is not strongly prognostic of success in VTE treatment (the most important inpatient indication for Lovenox), VTE prevention (the most important outpatient indication for Lovenox), or ACS (the indication addressed by M118).